WEBULL
WebtradeDownload

Merit Medical Stock In Focus After Earnings Beat And Higher 2026 Guidance

Simply Wall St · 19h ago
  • Merit Medical Systems reported third quarter 2026 sales of US$416.24 million and net income of US$42.31 million, alongside higher year to date sales and earnings and an increase to full year 2026 revenue guidance to US$1.635b to US$1.642b.
  • Management highlighted ongoing integration of recent deals and a continued focus on small tuck in acquisitions, while weighing carefully between in house development and inorganic growth to address product gaps across each platform.
  • Investors can now observe how Merit Medical Systems' raised full year revenue guidance may influence the existing investment narrative around margins and acquisitions.

Scan other acquisition driven healthcare stocks moving on similar themes to Merit Medical Systems in the hand picked 38 healthcare AI stocks list.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to be comfortable with a story built on execution, not big swings. The appeal is a mix of efficiency programs, a broad single use product range, and disciplined use of acquisitions to fill gaps in each platform. The raised 2026 revenue guidance looks incremental rather than transformative, so the core thesis still rests on consistent operating delivery.

The near term swing factor remains margin performance as tariffs, China pricing pressure and integration costs flow through. WRAPSODY CIE reimbursement progress and broader international demand still sit on the risk side. The latest update does not remove those issues. It does suggest current operations are tracking in line with internal plans.

The fresh earnings print is the clearest anchor for this acquisition story. Merit Medical Systems reported third quarter 2026 sales of US$416.24 million and net income of US$42.31 million, with year to date figures also higher than the prior period. That backdrop gives management more financial flexibility as it weighs new tuck in deals.

Raised full year revenue guidance to US$1.635b to US$1.642b links directly to the M&A playbook discussed on the call. As integration of Biolife StatSeal, C2 CryoBalloon and View Point Medical continues, investors can track whether future acquisitions support margin goals without magnifying existing risks around tariffs, WRAPSODY CIE reimbursement and slower China growth.

Merit Medical Systems' current analyst script points to revenues of US$1.9b and earnings of US$230.7 million by 2029, based on an assumed 6.2% yearly revenue growth rate and a move in profit from US$160.1 million today. This implies an earnings increase of about US$70.6 million by that forecast year.

Uncover why Merit Medical Systems' fair value indicates a 17% potential upside to its current price before the window for that discount narrows.

NasdaqGS:MMSI 1-Year Stock Price Chart
NasdaqGS:MMSI 1-Year Stock Price Chart

Exploring Other Perspectives

You might see the Merit Medical Systems story very differently if you lean into the bullish acquisition catalyst. The most optimistic analysts were already assuming revenue growth of 6.8% a year and earnings of about US$238.9 million by 2029 before this guidance bump. Their view suggests tuck in deals could justify richer expectations, although these forecasts all pre date the latest earnings and M&A comments, so you may want to compare several narratives and decide which version of the future feels more realistic.

Explore 2 other Merit Medical Systems fair value estimates, including one that suggests there could be as much as 30% upside from the current price.

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For More Ideas Beyond Merit Medical Systems?

If the Merit Medical Systems story has you thinking about portfolio balance, broaden the lens with a few targeted stock lists built from the Simply Wall St Screener. Each one focuses on a different angle so you can match ideas to your own risk tolerance and income goals.